Lateral Flow Assays Market Gains Momentum Across Infectious Disease Tests

The global lateral flow assays market size was estimated at USD 9.85 billion in 2024 and is projected to reach USD 17.44 billion by 2033, expanding at a CAGR of 6.98% from 2025 to 2033. This growth is driven by the increasing incidence of infectious diseases, continuous technological innovation in assay development, and the rising adoption of rapid diagnostic tools in both home-care and point-of-care settings.

Key Market Trends & Insights

  • North America dominated the global lateral flow assays market, accounting for 35.44% of total revenue in 2024.
  • The U.S. retained the largest share within the North American region in 2024.
  • By product, kits and reagents led the market with a 66.50% revenue share in 2024.
  • By application, clinical testing held the largest share at 74.33% in 2024.
  • By technique, the sandwich assays segment accounted for 38.75% revenue share in 2024.
  • By end use, hospitals and clinics were the leading segment, representing 34.90% of the market in 2024.

Market Size & Forecast

  • 2024 Market Size: USD 9.85 Billion
  • 2033 Market Size Projection: USD 17.44 Billion
  • CAGR (2025–2033): 6.98%
  • Largest Regional Market (2024): North America

Growing infectious disease burdens continue to drive demand for rapid diagnostic solutions. The WHO’s estimate of 263 million malaria cases in 2023 underscores the global need for fast, reliable, and affordable diagnostic platforms such as lateral flow assays. Technological improvements—including enhanced sensitivity, specificity, multiplexing capabilities, and integration with digital tools (smartphone-based readers, cloud platforms)—have expanded the application of lateral flow tests beyond infectious diseases into pregnancy testing, cardiovascular monitoring, veterinary diagnostics, environmental testing, and food safety.

Order a free sample PDF of the Lateral Flow Assays Market Intelligence Study, published by Grand View Research.

Key Lateral Flow Assays Company Insights

Major market players such as Abbott Laboratories, Thermo Fisher Scientific, and F. Hoffmann-La Roche AG continue to introduce advanced diagnostic kits. Notably, in March 2023, QuidelOrtho Corporation received De Novo FDA authorization for its Sofia 2 SARS + FIA test, marking the first FDA-cleared rapid antigen test for COVID-19.

Leading Lateral Flow Assays Companies

  • Abbott
  • Bio-Rad Laboratories, Inc
  • Siemens Healthineers AG
  • BIOMÉRIEUX
  • BD
  • QIAGEN
  • QuidelOrtho Corporation
  • Hoffmann-La Roche
  • DH Life Sciences, LLC
  • Quest Diagnostics
  • Qiagen N.V.

Conclusion

The lateral flow assays market is set for steady growth as the demand for rapid, easy-to-use diagnostic tools increases across healthcare, home testing, veterinary, and environmental applications. Strong technological progress—especially in digital integration and multiplexed testing—continues to enhance accuracy and expand use-cases. With infectious diseases remaining a major global challenge, the need for fast diagnostics will sustain market momentum through 2033.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.

Comments

Post a Comment

Popular posts from this blog

Urodynamic Equipment and Consumables Market Forecast: Anticipating Future Innovations

  The global urodynamic equipment and consumables market size is expected to reach USD 449.2 million in 2030 and is projected to grow at a CAGR of 5.7% from 2024 to 2030. This market is anticipated to grow at an unprecedented rate owing to growing geriatric population that exhibits greater vulnerability to urological dysfunctions. In addition, unprecedented upsurge in prevalence of bladder cancer poses high clinical urgency to adopt highly efficient diagnostics, which thereby broadens future growth prospects. In 2017, as per the American Cancer Society, bladder cancer accounted for 5.0% of all cancers in the U.S. The market is also driven by global increase in obesity. As per the Centers for Disease Control and Prevention, approximately 36.0% of adult population is obese. According to a research published in NCBI, obesity has increased the risk of developing various urological conditions, such as prostate cancer, nephrolithiasis, hypogonadism, and urinary tract infections. Furtherm...
Read more

Mobile Device Management Market Thrives with Growth in Cloud-Based Solutions

  According to a recent report by Grand View Research, Inc., the global   mobile device management (MDM) market   is projected to reach USD 28.37 billion by 2030, expanding at a CAGR of 24.5% from 2025 to 2030. This growth is primarily attributed to the increasing use of mobile devices in the workplace and the growing need to manage and secure them effectively. As smartphones, tablets, and other mobile devices become more prevalent, employees are increasingly using their personal devices for work—an approach known as Bring Your Own Device (BYOD). This trend is contributing to the rising number of mobile devices requiring centralized oversight and protection. MDM solutions offer organizations a unified platform to oversee and secure mobile devices, enabling functions such as security policy enforcement, device usage monitoring, and remote data wiping in cases of loss or theft. As companies continue to implement BYOD strategies or issue corporate devices to employees, deman...
Read more

U.S. Interventional Oncology Market Boosted by Aging Population

  The   U.S. interventional oncology market   size was estimated at USD 998.4 million in 2024 and is projected to reach USD 1,597 million by 2030, expanding at a CAGR of 8.17% from 2025 to 2030. This market growth is primarily driven by the increasing prevalence of cancer, continuous technological advancements in minimally invasive treatments, expanding investments in interventional oncology, and the aging population across the U.S. A major contributing factor is the rising incidence of cancer in the country. According to the American Cancer Society, approximately 2,041,910 new cancer cases are expected to be diagnosed in the U.S. in 2025, with 618,120 projected cancer-related deaths. As conventional therapies like chemotherapy and radiation often lead to significant side effects, minimally invasive techniques such as radiofrequency ablation and microwave ablation are becoming more popular. These procedures target tumors precisely while minimizing harm to surrounding tiss...
Read more